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and observed partial HSPC depletion in BM, spleen and peripheral 
blood. Notably, we did not observe histological lesions or increase 
in apoptosis (evaluated with Caspase 3 immunohistochemistry) due 
to organ toxicity in kidney, brain and BM of ADC-treated mice. To 
evaluate the efficacy of non-genotoxic conditioning in favouring 
HSPC engraftment early in life, we performed mismatched HSCT in 
WT ADC-conditioned mice, and compared it to transplantation after 
sublethal total body irradiation or without conditioning. Twenty weeks 
after transplant, we observed low but persistent donor chimerism 
in ADC-treated mice compared to irradiated controls in peripheral 
blood, BM, spleen and thymus.As reported in literature, very low level 
of donor cells engraftment is sufficient to restore bone phenotype in 
osteopetrotic mice. We hypothesized that ADC conditioning could 
successfully guarantee bone phenotype amelioration and reduction 
of the conditioning toxicity in the osteopetrotic mouse model. This 
approach may be even more advantageous in the GT setting, in which 
autologous HSCT avoids the risk of graft rejection. We plan to apply 
ADC conditioning on osteopetrotic mice before the transplant of 
lentiviral vector GT Lin- cells, to test the efficacy of our strategy on 
this severe bone disease model. Acknowledgements. This project has 
received funding from the European Calcified Tissue Society.
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The neurovascular unit (NVU) is a vital yet understudied component 
of the nervous system. Malfunction of non-neuronal cell types within 
the NVU, including endothelial cells, can facilitate the progression 
of neurological disorders (Yu et al, Frontiers in Neuroscience, 2020), 
but limited options for cell-type specific transgene delivery hamper its 
study. Adeno-associated virus (AAV) vectors for gene delivery to the 
brain are commonly administered via intra-cranial injections, resulting 
in tissue damage and limited, uneven spatial coverage. Systemic AAV 
delivery provides a non-invasive, brainwide alternative for genetic 
access. Having engineered vectors that efficiently cross the blood-
brain-barrier (BBB) with broad tropism in rodents (e.g. AAV-PHP.
eB), we turned our focus to engineering cell-type-specific vectors 
that could access vasculature without targeting other components of 
the NVU. Using M-CREATE directed evolution (Kumar et al, Nature 
Methods, 2020), we identified a family of endothelial-enriched capsid 
variants, including one named AAV-CAP.X1. Following intravenous 
(I.V.) injection, AAV-CAP.X1 targets vasculature with high cell-type 
specificity and efficiency throughout the body, including the brain. After 
injecting 3E11 vg total of AAV-CAP.X1 packaging CAG-GFP into adult 
C57BL/6J mice, 97% (+/- 0.8%) of the GFP+ area in the hippocampus 
are CD31+ (demonstrating specificity), and 73% (+/- 9.1%) of the 
CD31+ area in the hippocampus is GFP+ (proving efficiency; note 
that an increased dosage of 1E12 vg per mouse resulted in even greater 
CD31+ labeling without losing specificity). As AAV-CAP.X1 vascular 
infectivity in the periphery may complicate applications that focus on 
brain-specific endothelial transduction, we introduced point mutations 
on the AAV-CAP.X1 capsid and incorporated microRNA target sites 
into the cargo genome that successfully de-target AAV-CAP.X1 from 
the liver without impairing brain transduction. AAV-CAP.X1 can be 
used across multiple genetically diverse mouse strains, with efficient 
labeling of both capillaries and arteries in the brains of C57BL/6J, 
FVB/NJ, CBA/J, and BALB/cJ mice following I.V. administration. We 
also observed a significant increase in transduction compared to its 
parent capsid AAV9 on multiple human-derived cell lines in vitro. In 
its brain-targeted form, AAV-CAP.X1 could be paired with pre-clinical 
therapeutic cargo both to probe vascular contributions to neurological 
disease and to inform intervention strategies. More broadly, gene 
delivery via endothelial-tropic AAV capsids could, in principle, be 
applied to study diverse pathologies that may benefit from vascular 
remodeling. Our evolving knowledge regarding vascular pathology 
in COVID-19 that could underlie generalized organ dysfunction 
demonstrates the timeliness and potential importance of such vectors.
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Widespread transduction of the central nervous system (CNS) by viral 
or non-viral vectors still represents a considerable challenge in gene 
therapy. Local delivery of Adeno-Associated Virus (AAV) vectors to 
the CNS by intraparenchymal or intrathecal administration typically 
results in strong but heterogeneous transduction and is associated with 
potential risks related to invasive delivery. By contrast, intravascular 
delivery of engineered AAV vectors capable of crossing the blood-
brain barrier should allow a broader CNS transduction, thanks to the 
high density of the brain vascular network. We applied our previously 
described RNA-driven biopanning TRACER platform to perform 
directed evolution of an AAV9 capsid library in cynomolgus monkeys 
(Macaca fascicularis). Following two rounds of intravenous dosing and 
neuron-specific library selection, a synthetic pool of variants was tested 
by multiplexed RNA enrichment analysis. This yielded a series of capsid 
variants with enhanced performance relative to AAV9. Five selected 
candidates were tested individually by low dose intravenous injection 
and their tropism for the CNS analyzed by measuring transgene RNA 
expression, viral DNA biodistribution and immunohistochemistry. 
All five variants were markedly improved over AAV9, with a subset 
showing 10-fold or more improvement of transduction in the brain. 
The highest performing variant displayed more than 1,000-fold higher 
RNA expression in the brain and 100-fold higher in the spinal cord. 
Immunohistochemical analysis indicated that this enhanced new 
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